311 related articles for article (PubMed ID: 34133209)
1. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Stadler ZK; Maio A; Chakravarty D; Kemel Y; Sheehan M; Salo-Mullen E; Tkachuk K; Fong CJ; Nguyen B; Erakky A; Cadoo K; Liu Y; Carlo MI; Latham A; Zhang H; Kundra R; Smith S; Galle J; Aghajanian C; Abu-Rustum N; Varghese A; O'Reilly EM; Morris M; Abida W; Walsh M; Drilon A; Jayakumaran G; Zehir A; Ladanyi M; Ceyhan-Birsoy O; Solit DB; Schultz N; Berger MF; Mandelker D; Diaz LA; Offit K; Robson ME
J Clin Oncol; 2021 Aug; 39(24):2698-2709. PubMed ID: 34133209
[TBL] [Abstract][Full Text] [Related]
2. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
You YN; Borras E; Chang K; Price BA; Mork M; Chang GJ; Rodriguez-Bigas MA; Bednarski BK; Meric-Bernstam F; Vilar E
Dis Colon Rectum; 2019 Apr; 62(4):429-437. PubMed ID: 30730459
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
4. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.
Chen B; Zhang G; Li X; Ren C; Wang Y; Li K; Mok H; Cao L; Wen L; Jia M; Li C; Guo L; Wei G; Lin J; Li Y; Zhang Y; Han-Zhang H; Liu J; Lizaso A; Liao N
Aging (Albany NY); 2020 Feb; 12(4):3140-3155. PubMed ID: 32091409
[TBL] [Abstract][Full Text] [Related]
5. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
[TBL] [Abstract][Full Text] [Related]
6. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
9. Germline testing of
Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
[TBL] [Abstract][Full Text] [Related]
10. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
Ku GY; Kemel Y; Maron SB; Chou JF; Ravichandran V; Shameer Z; Maio A; Won ES; Kelsen DP; Ilson DH; Capanu M; Strong VE; Molena D; Sihag S; Jones DR; Coit DG; Tuvy Y; Cowie K; Solit DB; Schultz N; Hechtman JF; Offit K; Joseph V; Mandelker D; Janjigian YY; Stadler ZK
JAMA Netw Open; 2021 Jul; 4(7):e2114753. PubMed ID: 34251444
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
[TBL] [Abstract][Full Text] [Related]
13. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
15. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
Yurgelun MB; Chittenden AB; Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Qian ZR; Welch MW; Brais LK; Da Silva A; Bui JL; Yuan C; Li T; Li W; Masuda A; Gu M; Bullock AJ; Chang DT; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar MD; Wollison BM; Khalaf N; Perez K; Syngal S; Aguirre AJ; Hahn WC; Meyerson ML; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Nowak JA; Wolpin BM
Genet Med; 2019 Jan; 21(1):213-223. PubMed ID: 29961768
[TBL] [Abstract][Full Text] [Related]
16. Frequency of Pathogenic Germline Mutations in Early and Late Onset Familial Breast Cancer Patients Using Multi-Gene Panel Sequencing: An Egyptian Study.
Nassar A; Zekri AN; Kamel MM; Elberry MH; Lotfy MM; Seadawy MG; Hassan ZK; Soliman HK; Lymona AM; Youssef ASE
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672847
[TBL] [Abstract][Full Text] [Related]
17. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
18. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
19. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
[TBL] [Abstract][Full Text] [Related]
20. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]